Format
Sort by

Send to:

Choose Destination

Results: 4

1.

Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: results from the National Health and Wellness Survey.

Kalsekar I, Wagner JS, DiBonaventura M, Bates J, Forbes R, Hebden T.

Health Qual Life Outcomes. 2012 Jul 17;10:81. doi: 10.1186/1477-7525-10-81.

2.

Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.

Macfadden W, Adler CM, Turkoz I, Haskins JT, Turner N, Alphs L.

BMC Psychiatry. 2011 Oct 28;11:171. doi: 10.1186/1471-244X-11-171.

3.

A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression.

Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB.

J Psychiatr Res. 2009 Jan;43(3):205-14. doi: 10.1016/j.jpsychires.2008.05.003. Epub 2008 Jun 30.

4.

Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression.

Alexopoulos GS, Canuso CM, Gharabawi GM, Bossie CA, Greenspan A, Turkoz I, Reynolds C 3rd.

Am J Geriatr Psychiatry. 2008 Jan;16(1):21-30. Epub 2007 Oct 10.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk